1
Pharmacogenetics-guided Isoniazid Dosing in TB-HIV
Condition(s):TuberculosisLast Updated:January 25, 2022Recruiting
Isoniazid: 313 Clinical Trials, Page 1 of 32
Hide Studies Not Open or Pending
2
Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)
Condition(s):Silicosis TuberculosisLast Updated:April 5, 2019Recruiting
3
Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana
Condition(s):Tuberculosis; HIV InfectionsLast Updated:February 6, 2014Completed
4
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
Condition(s):Tuberculosis; Drug-Induced Liver Injury; Adverse Drug EventLast Updated:February 28, 2020Completed
5
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Condition(s):HIV Seropositivity; Pregnancy; Tuberculosis InfectionLast Updated:November 16, 2021Not yet recruiting
6
Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid
Condition(s):HIVLast Updated:June 21, 2017Unknown status
7
Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis
Condition(s):Infertility, Female; Recurrent Implantation Failure; Genital Tuberculoses, Female; Genital Tuberculosis, LatentLast Updated:August 27, 2020Not yet recruiting
8
NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis
Condition(s):HepatotoxicityLast Updated:March 17, 2014Unknown status
9
Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)
Condition(s):Pulmonary TuberculosisLast Updated:February 28, 2011Terminated
10
Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals
Condition(s):Tuberculosis; HIVLast Updated:October 30, 2019Completed